Location of Repository

Blood monocytes in cystic fibrosis

By Satish Ramakrishna Rao


Background: Neutrophilic inflammation causes lung damage in cystic fibrosis\ud (CF). Recent data from animal models and other chronic pulmonary inflammatory\ud conditions suggest that the monocytes/macrophages may be an important driver of\ud airway inflammation. CF may be associated with increased airway levels of\ud chemoattractants for monocytes and resulting expansion of CD14++ small\ud macrophages. I sought to assess the levels of monocyte chemoattractants CCL2\ud and CX3CL1 in the blood and airways of CF patients, and expression of their\ud respective receptors CCR2 and CX3CR1 on monocytes. In a pilot study, I sought\ud evidence for expansion of airway CD14++ small macrophages.\ud Methods: Blood was obtained from 32 CF patients and 25 healthy controls; and\ud induced sputum (IS) from 24 CF patients and 17 healthy controls. Flow cytometry\ud was used to determine expression of CCR2 and CX3CR1 on CD14++ and\ud CD14+CD16+ blood monocytes and to characterise IS airway macrophages.\ud CCL2 and CX3CL1 levels in blood and IS were determined by ELISA.\ud Results: Absolute count of total monocytes and monocytes subpopulations was\ud not different between CF and controls. Serum CCL2, but not CX3CL1, was\ud increased in CF patients (p=0.006). Similarly, CF was associated with increased IS\ud CCL2, but not CX3CL1 (190.6 vs. 77.3 pg/mL; p=0.029). CCR2 was expressed on\ud CD14++ monocytes but not on CD14+CD16+ monocytes. Both CD14+CD16+\ud and CD14++ cells expressed CX3CR1 but the expression was higher in\ud CD14+CD16+ cells compared to the CD14++ cells. There was no difference in\ud expression of both chemokine receptors by either monocyte subpopulation\ud between CF and controls. Small macrophages were significantly increased in CF\ud airways (p=0.018).\ud Conclusion: CCL2, but not CX3CL1 is increased in the airway and blood of CF\ud patients. Blood monocytes from CF patients are phenotypically competent to\ud respond to CCL2, since they express normal levels of CCR2. Preliminary results\ud suggest an expansion of small macrophages in CF airways

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/7345

Suggested articles



  1. (2004). 1). "Cytokine secretion by cystic fibrosis airway epithelial cells."
  2. (2002). 1). "Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis."
  3. (2000). 1). "G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages."
  4. (2002). 1). "Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis."
  5. (2002). 1). "The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice."
  6. (2003). 15). "Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis."
  7. (2003). 15). "Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis."
  8. (1993). 15). "The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients."
  9. (2003). 16). "Fractalkine preferentially mediates arrest and migration of CD16+ monocytes."
  10. (2004). A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation."
  11. (1953). Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease."
  12. (1953). Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas."
  13. (2001). Alveolar JE/MCP-1 and endotoxin synergize to provoke lung cytokine upregulation, sequential neutrophil and monocyte influx, and vascular leakage in mice."
  14. (1958). An aerosol method of producing bronchial secretions in human subjects: a clinical technic for the detection of lung cancer."
  15. (2000). Anti-monocyte chemoattractant protein1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis."
  16. (2000). Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus."
  17. (1997). Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis."
  18. (1998). Apoptosis. Phagocytic docking without shocking."
  19. (1995). Apr). "Early pulmonary inflammation in infants with cystic fibrosis."
  20. (1988). Apr). "Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis."
  21. (2007). Association between pulmonary function and sputum biomarkers in cystic fibrosis".
  22. (2002). Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial."
  23. (2006). Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients."
  24. (2003). Aug). "Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis."
  25. (1997). Aug). "Current understanding of the inflammatory process in cystic fibrosis: onset and etiology."
  26. (1999). Aug). "Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa."
  27. (2000). Aug). "Inflammation and infection in naive human cystic fibrosis airway grafts."
  28. (1993). Aug). "Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis."
  29. (2002). Aug). "Monitoring inflammation in CF.
  30. (2004). Aug). "Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2."
  31. (1995). Aug). "The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis."
  32. (2003). Blood monocytes consist of two principal subsets with distinct migratory properties."
  33. blood monocytes in cystic fibrosis. Thorax 2005;60(suppl 2):ii93. Presented at CF session,
  34. (1995). Blood monocytes of untreated asthmatics exhibit some features of tissue macrophages."
  35. (1981). Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline."
  36. (1985). Bronchodilators increase airway instability in cystic fibrosis."
  37. (1994). C-reactive protein is not a useful indicator of intermittent bacterial colonization in early lung disease of patients with cystic fibrosis."
  38. (2000). CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis."
  39. (1994). CD14 is a pattern recognition receptor."
  40. (1999). CD14."
  41. (1999). CD14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immunosuppressive therapy."
  42. (2004). Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers."
  43. (1999). Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression."
  44. (2001). Chemokines and disease."
  45. (2000). Chemokines: a new classification system and their role in immunity."
  46. (2003). Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients."
  47. (1998). Circulating immunoreactive interleukin-6 in cystic fibrosis."
  48. (1999). Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases."
  49. (1989). Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges."
  50. (2000). CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms."
  51. (2007). Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy."
  52. (2007). Cystic fibrosis mortality and survival in the UK: 1947-2003."
  53. (1948). Cystic fibrosis of the pancreas."
  54. (2003). Cystic fibrosis."
  55. (2004). Dec). "Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load."
  56. (1998). Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis."
  57. (1997). Defective antigen presentation by lavage cells from terminal patients with cystic fibrosis."
  58. (2000). Differential chemokine receptor expression and function in human monocyte subpopulations."
  59. (1986). Distribution of blood monocytes between a marginating and a circulating pool."
  60. (2005). DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha."
  61. (2003). Efficacy of environmental measures in reducing potentially infectious bioaerosols during sputum induction."
  62. (1978). Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol."
  63. (2005). Eradication of early Pseudomonas aeruginosa infection."
  64. (2001). Expansion of CD4+CD16+ blood monocytes in patients with chronic renal failure undergoing dialysis: possible involvement of macrophage colony-stimulating factor."
  65. (2004). Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis."
  66. (2004). Feb). "Structural airway abnormalities in infants and young children with cystic fibrosis."
  67. (2006). Fractalkine in rheumatoid arthritis and allied conditions."
  68. (2004). Fractalkine in vascular biology: from basic research to clinical disease."
  69. (2004). Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids."
  70. (1999). Fractional analysis of sequential induced sputum samples during sputum induction: evidence that different lung compartments are sampled at different time points."
  71. (2006). Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma."
  72. (1996). Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection."
  73. (1951). Heat prostration in fibrocystic disease of the pancreas and other conditions."
  74. (1998). Human chemokines: role in lymphocyte trafficking."
  75. (1989). Human Fc receptors for IgG."
  76. (1990). Hypertonic saline increases vascular permeability in the rat trachea by producing neurogenic inflammation."
  77. (1989). Identification and characterization of a novel monocyte subpopulation in human peripheral blood."
  78. (1989). Identification of the cystic fibrosis gene: genetic analysis."
  79. (2003). In celebration of expectoration: induced sputum indices as outcome measures in cystic fibrosis."
  80. (1999). Increased CCL2 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics."
  81. (1996). Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements."
  82. (1997). Induced sputum cell and fluidphase indices of inflammation: comparison of treatment with dithiothreitol vs phosphate-buffered saline."
  83. (1988). Infants with cystic fibrosis: pulmonary function at diagnosis."
  84. (2001). Interferon-gamma stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence."
  85. (2001). Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD).
  86. (1984). Isolation and functional characteristics of FcR+ and FcR- human monocyte subsets."
  87. (1999). Jul). "Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients."
  88. (2000). Jul). "Sputum induction in young cystic fibrosis patients."
  89. (1998). Long-term azithromycin may improve lung function in children with cystic fibrosis."
  90. (2001). Lymphocyte traffic control by chemokines."
  91. (2004). Macrolide antibiotics for cystic fibrosis." Cochrane Database Syst Rev(2):
  92. (2004). Mar). "Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients."
  93. (2002). Mar). "The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus."
  94. (1988). Mediator release in an isolated airway segment in subjects with asthma."
  95. (2006). Migratory fate and differentiation of blood monocyte subsets."
  96. (1997). MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation."
  97. (1999). Molecular uncoupling of fractalkinemediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation."
  98. (2000). Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD."
  99. (2003). Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies."
  100. (1999). Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice."
  101. (2000). Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines."
  102. (2003). Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis."
  103. (1996). Monocytes can phagocytose Gram-negative bacteria by a CD14-dependent mechanism."
  104. (2001). Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14."
  105. (2006). New insights into pulmonary inflammation in cystic fibrosis."
  106. (2006). New insights into pulmonary inflammation in cystic fibrosis." Arch Dis Child 91(9): 786
  107. (2007). No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations."
  108. (2002). Nov). "Bacterial stimulation of epithelial G-CSF and GM-CSF expression promotes PMN survival in CF airways."
  109. (1993). Nov). "Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients."
  110. (2004). Nov). "Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers."
  111. (2002). Oct). "CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis."
  112. (2001). Oct). "Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis."
  113. (2002). Oct). "Early airway infection, inflammation, and lung function in cystic fibrosis."
  114. (1997). Oct). "Lower airway inflammation in infants and young children with cystic fibrosis."
  115. (2004). Oct). "Lung inflammation as a therapeutic target in cystic fibrosis."
  116. (2007). Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis." Cochrane Database Syst Rev(4): CD001505.
  117. (2000). Oral steroids for cystic fibrosis." Cochrane Database Syst Rev(2):
  118. (1970). Origin and kinetics of monocytes and macrophages."
  119. (1982). Phagocytosis of Pseudomonas aeruginosa by polymorphonuclear leukocytes and monocytes: effect of cystic fibrosis serum."
  120. (2007). Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis."
  121. (2005). Phenotypic characterization of blood monocytes from HIV-infected individuals."
  122. (1993). Phenotypical and functional characterization of Fc gamma receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high accessory and antiviral activity."
  123. (1991). Practical statistics for medical research. London: Chapman and
  124. (1991). Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment."
  125. (1999). Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication."
  126. (2000). Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines."
  127. (2006). RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study."
  128. (2006). Regulation of intestinal dendritic cell migration and activation by plasmacytoid dendritic cells, TNF-alpha and type 1 IFNs after feeding a TLR7/8 ligand."
  129. (1996). Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma."
  130. (2004). Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebocontrolled trial."
  131. (2007). Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial."
  132. (2006). Resident alveolar macrophages are replaced by recruited monocytes in response to endotoxin-induced lung inflammation."
  133. (2001). Role of fractalkine in leukocyte adhesion and migration and in vascular injury."
  134. (2003). Safety and use of sputum induction in children with cystic fibrosis."
  135. (2002). Safety of sputum induction."
  136. (2000). Sep). "CD14+CD16+ monocyte subpopulation in Kawasaki disease."
  137. (2001). Sep). "G551D CF mice display an abnormal host response and have impaired clearance of Pseudomonas lung disease."
  138. (2004). Sep). "Interleukin 8 Secretion from Monocytes of Subjects Heterozygous for the {Delta}F508 Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutation Is Altered."
  139. (1998). Sep). "Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro."
  140. (1998). Sep). "Therapies aimed at airway inflammation in cystic fibrosis."
  141. (1978). Serial lung function studies in cystic fibrosis in the first 5 years of life."
  142. (2008). Small Macrophages in Cystic Fibrosis Airways. E-poster presentation at European respiratory Society Conference,
  143. (1995). Some technical factors influencing the induction of sputum for cell analysis."
  144. (1997). Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment."
  145. (2003). Sputum induction in research: beware of the beast."
  146. (2002). Sputum induction."
  147. (2003). State of the Art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?"
  148. (2004). Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response."
  149. (2004). Systemic inflammatory mediators and cystic fibrosis genotype."
  150. (2007). Systemic monocyte chemoattractant concentrations and receptor expression in cystic fibrosis. Presented as poster discussion at American Thoracic Society Conference,
  151. (2001). Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection."
  152. (2003). Targeting monocyte chemoattractant protein1 signalling in disease."
  153. (1996). The association between occupation and tuberculosis. A population-based survey."
  154. (1993). The contribution of neurogenic reflexes to hypertonic saline-induced bronchoconstriction in asthma."
  155. (1999). The effect of processing on inflammatory markers in induced sputum."
  156. (1966). The intravascular lifespan of monocytes."
  157. (1972). The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells."
  158. (1980). The mononuclear phagocyte system."
  159. (2002). The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice."
  160. (1996). TNF-lpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients."
  161. (1992). Transforming growth factor-beta in synovial fluids modulates Fc gamma RII (CD16) expression on mononuclear phagocytes."
  162. (1992). Use of induced sputum cell counts to investigate airway inflammation in asthma."

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.